Equities Analysts Issue Forecasts for GH Research PLC’s FY2027 Earnings (NASDAQ:GHRS)

GH Research PLC (NASDAQ:GHRS – Get Rating) – Stock analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of GH Research in a note issued to investors on Monday, March 13th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.01) per share for the year. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($1.07) per share.

Several other equities analysts have also issued reports on the company. UBS Group began coverage on GH Research in a research note on Thursday, December 15th. They set a “buy” rating on the stock. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $33.00 target price on shares of GH Research in a research note on Thursday, March 2nd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $46.25.

GH Research Trading Down 0.8 %

GHRS opened at $8.65 on Tuesday. The stock’s 50-day moving average price is $9.64 and its 200 day moving average price is $10.82. GH Research has a 12-month low of $7.93 and a 12-month high of $20.32. The firm has a market cap of $437.00 million, a price-to-earnings ratio of -20.12 and a beta of 0.80.

Institutional Investors Weigh In On GH Research

Several large investors have recently bought and sold shares of the stock. VR Adviser LLC increased its holdings in GH Research by 5.5% during the 4th quarter. VR Adviser LLC now owns 3,517,125 shares of the company’s stock worth $34,186,000 after purchasing an additional 183,971 shares during the period. Citadel Advisors LLC increased its holdings in GH Research by 2.2% during the 2nd quarter. Citadel Advisors LLC now owns 1,303,470 shares of the company’s stock worth $13,009,000 after purchasing an additional 27,738 shares during the period. Verition Fund Management LLC increased its holdings in GH Research by 47.6% during the 4th quarter. Verition Fund Management LLC now owns 897,860 shares of the company’s stock worth $8,682,000 after purchasing an additional 289,736 shares during the period. Morgan Stanley increased its holdings in GH Research by 7.1% during the 4th quarter. Morgan Stanley now owns 524,115 shares of the company’s stock worth $5,094,000 after purchasing an additional 34,779 shares during the period. Finally, Millennium Management LLC increased its holdings in GH Research by 585.8% during the 4th quarter. Millennium Management LLC now owns 69,339 shares of the company’s stock worth $671,000 after purchasing an additional 59,228 shares during the period. Hedge funds and other institutional investors own 62.55% of the company’s stock.

GH Research Company Profile

(Get Rating)

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).